English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA global study of a combination drug therapy, led by an investigator at Huntsman Cancer Institute, has shown improved overall survival rates for metastatic prostate cancer compared to standard treatments.
Tag: Combination Therapy
Quadruple Therapies and the Future of Multiple Myeloma Treatment
ASCO: Treatment options for multiple myeloma are shifting rapidly, with new patients increasingly being treated with a 4-part drug combination that includes a new immunotherapy agent. What does this mean for patients, and how will treatment change in the future?
New Frontiers in Treating GI Cancers
Gastrointestinal cancers were once diagnosed primarily by location. A tumor in the liver was liver cancer, while one in the pancreas was pancreatic. The few chemotherapy treatments available affected the entire patient—sometimes causing difficult side effects.
Breast Cancer at 30?
Amanda Butler and Isabella Bugatti, both just entering their 30s, were blindsided by a diagnosis that is on the rise among women their age: breast cancer.
Winners of the ASTRO-Sumitomo Pharma-Pfizer Alliance new combination therapy challenge announced
The American Society for Radiation Oncology (ASTRO) today announced the three winning research proposals for the 2022 ASTRO-Myovant Sciences (now known as Sumitomo Pharma)-Pfizer Alliance New Combination (Relugolix-Radiation) Therapy Challenge.
MD Anderson Research Highlights for April 19, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
MD Anderson Research Highlights: AACR 2023 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. This special edition features presentations by MD Anderson researchers at the American Association for Cancer Research (AACR) Annual Meeting 2023.
MD Anderson Research Highlights for March 29, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
MD Anderson Research Highlights for February 22, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments include a new understanding of how HPV drives cancer development, a combination therapy to overcome treatment resistance in mantle cell lymphoma, novel insights into memory T cell formation and potential therapeutic strategies for brain cancers, improved survival outcomes for metastatic colorectal cancer, targeting myeloperoxidase to improve immunotherapy responses in melanoma, and preclinical results of a combination therapy that could effectively treat a subset of acute myeloid leukemia.
MD Anderson Research Highlights for January 11, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.
MD Anderson Research Highlights for November 30, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.
MD Anderson Research Highlights for September 28, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include an investigation into the efficacy of dexamethasone for dyspnea relief, a combination therapy for hairy cell leukemia, an analysis of RAS mutations and their prognostic value in acute myeloid leukemia (AML), a possible new combination therapy for basal-like breast cancer, and swallowing exercises to improve the quality of life for patients with head and neck cancer undergoing radiotherapy.
Plant virus plus immune cell-activating antibody clear colon cancer in mice, prevent recurrence
A new combination therapy to combat cancer could one day consist of a plant virus and an antibody that activates the immune system’s “natural killer” cells, shows a study by researchers at the University of California San Diego. In mouse models of colon cancer, the combination therapy eliminated all tumors and prevented their recurrence, which in turn resulted in 100% survival. The therapy also increased survival in mouse models of melanoma.
Researchers identify potential combination therapy for aggressive lung cancer
The combination approach uses immune checkpoint inhibitors with ATRA, a safe medication that is widely used to treat leukemia.